Clinical trials: Bladder
Overactive Bladder
Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder
The specific aim of this trial is to determine if hydrodistention at the time of intradetrusor injection of botulinum toxin A has additional benefit in patients with refractory overactive bladder (OAB) and urgency symptoms…
- Trial name
- HydrA (NCT02995967)
- Testing
- Hydrodistention, Botulinum toxin-A
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Overactive Detrusor
Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
The purpose of this study is to find out whether plantarflexion has an effect on the degree of urinary urgency and on the amplitude of detrusor contraction during filling cystometry in patients with detrusor overactivity (DO).
- Trial name
- DO (NCT01837654)
- Testing
- Plantarflexion 2nd wave, Plantarflexion - 3rd wave
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Assaf-Harofeh Medical Center
Overactive Bladder
Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
This is a prospective, randomized, double-blind study comparing intravesical injection of BOTOX to placebo. Study subjects will be randomized (1:1 ratio) to one of the following treatment groups:
- Trial name
- NCT01220726
- Testing
- Botox
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Overactive Bladder
Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms
Ureteroscopy is a common procedure in Urology that patients undergo daily to deal with a variety of ailments. These procedures often require that the bladder be filled and emptied with sterile water or saline several times during…
- Trial name
- NCT02865395
- Testing
- Belladonna and Opium Suppository, Rectal Exam
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Campbell Grant
Urinary Bladder, Neurogenic
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
The proposed study is a randomized, double blind placebo controlled multicenter study to determine the effectiveness of mirabegron in the treatment of neurogenic bladder dysfunction.
- Trial name
- NCT02044510
- Testing
- Mirabegron
- Where
- 5 sites in Canada
- Volunteers
- 32 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Urinary Bladder, Overactive
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB).
- Trial name
- NCT01314872
- Testing
- Vibegron, Tolterodine ER
- Volunteers
- 1,395 people
- Sponsor
- Merck Sharp & Dohme LLC
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Urinary Bladder Neoplasms
Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy
The purpose of this clinical trial was to demonstrate the benefit of the immunotherapeutic product recMAGE-A3 + AS-15 given to patients with bladder cancer after removal of the bladder.
- Trial name
- MAGNOLIA (NCT01435356)
- Testing
- recMAGE-A3 + AS15 ASCI
- Where
- 50 sites in Czechia, France and 8 more
- Volunteers
- 83 people
- Sponsor
- European Association of Urology Research Foundation
Overactive Bladder, Overactive Urinary Bladder
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
The study is designed to investigate the effects of the investigational drug vibegron (MK-4618) compared to placebo on maximum urinary bladder capacity in women with overactive bladder.
- Trial name
- NCT01500382
- Testing
- Vibegron, Tolterodine ER, Prophylactic Antibiotic
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)
This study will investigate the impact of impaired renal function on the plasma pharmacokinetics of vibegron (MK-4618) to guide use of vibegron in clinical trials in participants with overactive bladder and to guide…
- Trial name
- NCT01628042
- Testing
- Vibegron 100 mg
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index…
- Trial name
- NCT01737684
- Testing
- Vibegron
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
A Clinical Trial To Assess Fesoterodine On Treatment Satisfaction And Symptom Improvement In Overactive Bladder Patients
To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.
- Trial name
- NCT00425100
- Testing
- fesoterodine fumarate
- Where
- 60 sites in United States, Belgium and 7 more
- Volunteers
- 516 people
- Sponsor
- Pfizer
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Overactive Bladder
This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for…
- Trial name
- NCT00943735
- Testing
- Fesoterodine, Your Way
- Volunteers
- 774 people
- Sponsor
- Pfizer
Urinary Bladder, Overactive
A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.
Patients with overactive bladder are often treated with tolterodine, a medication that helps relax the bladder, helping symptoms of urinary incontinence and urinary frequency.
- Trial name
- NCT01302054
- Testing
- Fesoterodine 8 mg
- Where
- 176 sites in United States, Bulgaria and 13 more
- Volunteers
- 990 people
- Sponsor
- Pfizer
Urinary Bladder Neoplasms
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
This trial is for people with bladder cancer that has spread. The purpose of this research study is to see if the chemotherapy combination of gemcitabine and cisplatin plus paclitaxel is safe and effective treatment for bladder…
- Trial name
- NCT02560038
- Testing
- Gemcitabine, Paclitaxel, Cisplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Overactive Bladder, Urinary Incontinence
Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous Therapy
This is a observational study in patients treated with fesoterodine (Toviaz), who have failed on previous treatment for overactive bladder.
- Trial name
- NCT00691093
- Testing
- fesoterodine
- Where
- 65 sites in Slovakia
- Volunteers
- 823 people
- Sponsor
- Pfizer
Overactive Bladder
Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation.
- Trial name
- DRIVE (NCT00465894)
- Testing
- Extended Release Tolterodine LA, Intra Vaginal Estradiol Cream
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Interstitial Cystitis, Mindfulness
Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a poorly understood disease with unreliable treatments. Although it is not known what causes it for certain, we do know that life stressors may make the disease worse or…
- Conditions
- Interstitial Cystitis, Mindfulness, Complementary Medicine, Painful Bladder Syndrome
- Trial name
- NCT02457182
- Testing
- Mindfulness-based Stress Reduction (MBSR), Usual medical therapy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of New Mexico